Iterum Therapeutics announces FDA approval of Orlynvah
Iterum Therapeutics (ITRM) plc announced that the U.S. Food and Drug Administration has approved Iterum’s new drug application for ...
FiercePharma6h
After prior rejection, Iterum nabs long-sought FDA nod for oral UTI drug Orlynvah
Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...
Scientific American13h
Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from Settled
Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known ...
Heartland1d
Use of Weight Loss Drug Widespread, and Costly
As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...
How To Boost the Weight-Loss Benefits of Ozempic With Easy Tips
Ozempic is arguably the buzziest buzzword in our culture today. But we still have plenty of questions about the type 2 ...
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...
FiercePharma2d
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
The war is on between compounding pharmacies making knockoff versions of popular weight loss ... FDA to convene an advisory ...
BioSpace2d
Novo Makes Case to FDA That Semaglutide Is Too Complex for Compounders to Produce
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...